anti-IL-15 receptor beta chain antibody

An anti-IL-15 receptor beta chain antibody (also known as an anti-CD122 antibody) is a monoclonal antibody that targets CD122, the shared beta subunit of the interleukin-2 (IL-2) and interleukin-15 (IL-15) receptors. CD122 is expressed on natural killer (NK) cells, memory CD8+ T cells, and other lymphocyte subsets. By blocking CD122, these antibodies inhibit both IL-2 and IL-15 signaling pathways, which are critical for the survival, activation, and proliferation of pathogenic T cells and NK cells involved in autoimmune and inflammatory diseases. This therapeutic approach is being investigated for conditions such as vitiligo, celiac disease, alopecia areata, and type 1 diabetes, with clinical-stage candidates including FB102 (argenx/Forte Biosciences), ANB033 (First Tracks Biotherapeutics), and INCA34460 (Incyte).

Other names

anti-CD122 antibodyanti-CD-122 antibodyanti-CD 122 antibodyanti-IL-15 receptor beta antibodyanti-IL15 receptor beta antibodyanti-IL 15 receptor beta antibodyanti-IL-15R beta antibodyanti-IL15R beta antibodyanti-IL 15R beta antibodyanti-IL-15Rβ antibodyanti-IL-2 receptor beta chain antibodyanti-IL2 receptor beta chain antibodyanti-IL 2 receptor beta chain antibodyanti-IL-2/IL-15 receptor beta antibodyanti-IL-2R beta antibodyanti-IL2R beta antibodyanti-IL 2R beta antibodyTM-beta1TM-beta-1TM-beta 1TM-β1